Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Analyst Ratings
Moderate Buy
12 Buy
14 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VRTX Stock 12 Month Forecast
Average Price Target
$513.67
▲(12.78%Upside)
| Highest Price Target$621.00 | Average Price Target$513.67 | Lowest Price Target$423.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$453
Hold
-0.54%
Downside
Reiterated
05/22/25
Vertex Pharmaceuticals' strong revenue growth and product launches are positive, but the score is impacted by short-term profitability issues, weak technical indicators, and valuation concerns due to a negative P/E ratio. Confidence in future growth, supported by a solid balance sheet and strategic initiatives like the stock buyback, provides some balance.
Canaccord Genuity
$424
Hold
-6.91%
Downside
Reiterated
06/12/25
Goldman Sachs
$621
Buy
36.35%
Upside
Reiterated
06/10/25
Bank of America Securities
$567
Buy
24.49%
Upside
Reiterated
06/09/25
William Blair
―
Buy
―
Reiterated
06/06/25
BMO Capital
$557
Buy
22.30%
Upside
Reiterated
06/06/25
RBC Capital
$423
Hold
-7.12%
Downside
Reiterated
06/06/25
Barclays
$499
Hold
9.56%
Upside
Reiterated
05/30/25
UBS
$583→$582
Buy
27.79%
Upside
Reiterated
05/29/25
Jefferies
$575
Buy
26.25%
Upside
Reiterated
05/27/25
Bernstein
―
Hold
―
Assigned
05/27/25
Erste Group
―
Hold
―
Downgraded
05/23/25
Scotiabank
$442
Hold
-2.95%
Downside
Reiterated
05/21/25
Evercore ISI
$510
Buy
11.98%
Upside
Reiterated
05/20/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$453
Hold
-0.54%
Downside
Reiterated
05/22/25
Vertex Pharmaceuticals' strong revenue growth and product launches are positive, but the score is impacted by short-term profitability issues, weak technical indicators, and valuation concerns due to a negative P/E ratio. Confidence in future growth, supported by a solid balance sheet and strategic initiatives like the stock buyback, provides some balance.
Canaccord Genuity
$424
Hold
-6.91%
Downside
Reiterated
06/12/25
Goldman Sachs
$621
Buy
36.35%
Upside
Reiterated
06/10/25
Bank of America Securities
$567
Buy
24.49%
Upside
Reiterated
06/09/25
William Blair
―
Buy
―
Reiterated
06/06/25
BMO Capital
$557
Buy
22.30%
Upside
Reiterated
06/06/25
RBC Capital
$423
Hold
-7.12%
Downside
Reiterated
06/06/25
Barclays
$499
Hold
9.56%
Upside
Reiterated
05/30/25
UBS
$583→$582
Buy
27.79%
Upside
Reiterated
05/29/25
Jefferies
$575
Buy
26.25%
Upside
Reiterated
05/27/25
Bernstein
―
Hold
―
Assigned
05/27/25
Erste Group
―
Hold
―
Downgraded
05/23/25
Scotiabank
$442
Hold
-2.95%
Downside
Reiterated
05/21/25
Evercore ISI
$510
Buy
11.98%
Upside
Reiterated
05/20/25
Best Analysts Covering Vertex Pharmaceuticals
1 Month
xxx
Success Rate
18/27 ratings generated profit
Average Return
+1.82%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.82% per trade.
3 Months
xxx
Success Rate
19/27 ratings generated profit
Average Return
+4.96%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.37% of your transactions generating a profit, with an average return of +4.96% per trade.
1 Year
Success Rate
13/17 ratings generated profit
Average Return
+11.55%
reiterated a sell rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +11.55% per trade.
2 Years
xxx
Success Rate
28/32 ratings generated profit
Average Return
+29.32%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +29.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VRTX Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
1
0
0
0
0
Buy
51
45
32
33
29
Hold
36
31
22
28
28
Sell
3
2
0
0
0
Strong Sell
0
0
0
0
0
total
91
78
54
61
57
Each month's total comprises the sum of three months' worth of ratings.
VRTX Financial Forecast
VRTX Stock Forecast FAQ
What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 513.67.
What is VRTX’s upside potential, based on the analysts’ average price target?
Vertex Pharmaceuticals has 12.78% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VRTX a Buy, Sell or Hold?
Vertex Pharmaceuticals has a consensus rating of Moderate Buy which is based on 12 buy ratings, 14 hold ratings and 0 sell ratings.
What is Vertex Pharmaceuticals’s price target?
The average price target for Vertex Pharmaceuticals is 513.67. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $621.00 ,the lowest forecast is $423.00. The average price target represents 12.78% Increase from the current price of $455.45.
The highest analyst price target is $621.00 ,the lowest forecast is $423.00. The average price target represents 12.78% Increase from the current price of $455.45.
What do analysts say about Vertex Pharmaceuticals?
Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.
How can I buy shares of VRTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.